Paweł Kozielewicz

Paweł Kozielewicz

Biträdande Lektor | Teamledare
Besöksadress: Solnavägen 9, Biomedicum, 17165 Solna
Postadress: C3 Fysiologi och farmakologi, C3 FyFa Receptorbiologi Molekylär farmakologi av G protein-kopplade receptorer, 171 77 Stockholm
Del av:

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Proof-of-concept studies to propose an orphan G protein-coupled receptor GPR61 as a novel target in metabolic disorders
    SRP Diabetes Blue Sky Grant 2025
    1 May 2025 - 31 December 2026
  • Understanding the role of orphan GPCR GPR61 in obesity
    Karolinska Institutet Research Foundation
    25 November 2024 - 24 November 2026
  • Targeting G protein-coupled receptors in cancers
    Karolinska Institutet
    10 October 2024 - 9 October 2027
  • GPR34, GPR65 och GPR183 som terapeutiska mĺl i blodcancer
    Jeanssons Stiftelser
    13 December 2023 - 12 December 2024
  • Swedish Research Council
    1 January 2023 - 31 December 2026
    G-protein-coupled receptors (GPCRs) constitute 30% of all drug targets and are often overexpressed and mutated in cancer, including haematological disorders. There is an immediate need for better treatment for patients suffering from peripheral blood cancers. For example, 41% of people diagnosed with Non-Hodgkin Lymphoma are predicted to survive less than 10 years. In the proposed project, I will focus on the GPCRs GPR34, GPR65 and GPR183. I have selected these three receptors based on the current literature and my preliminary data which support the hypothesis that they can be potential therapeutic targets. To test my assumptions, I will develop and employ novel biophysical BRET-based tools to assess ligand-induced conformational changes in GPR34/65/183 together with receptor-mediated G protein activation and recruitment of intracellular transducer proteins. These assays will be used to test the activity of small ligands predicted from large in silico screenings. Subsequently, I will analyse if up- or down-regulation, and mutations in GPR34/65/183 influence the functions of in vitro cultured cells of haematological origin and healthy B- and T-cells. My research will provide the first complexed insight into the role of these GPCRs in malignant and normal blood cells, and will aid the discovery of novel compounds with exciting prospects as anti-cancer drugs

Anställningar

  • Biträdande Lektor, Fysiologi och farmakologi, Karolinska Institutet, 2023-2029

Examina och utbildning

  • Habilitation in Medical Sciences, Medical University of Lublin, 2022
  • PhD in Clinical and Experimental Medicine, University of Birmingham, 2017
  • Master's of Pharmacy, Medical University of Warsaw, 2013

Uppdrag

  • Biträdande PD för mastersprogrammet, The Global Master's Programme in Translational Physiology and Pharmacology, Department of Physiology and Pharmacology, Karolinska Institutet, 2025-
  • Teamledare, Molecular Pharmacology of GPCRs, Department of Physiology and Pharmacology, Karolinska Institutet, 2024-

Nyheter från KI

Kalenderhändelser från KI